The number of people aged 65 and over is expected to increase from the current total of the 39 million to over 72 million by the year 2030, with a disproportionate share of the growth being in the very old - age 85 and older. This along with a rise in chronic disease and obesity within the same population will strain societal resources and could significantly drive up US healthcare and senior living expenses, paid for by all. Considering the implications of this demographic bomb on society sits an unrealized business opportunity; the fact that the majority of adults would prefer to "age in place". Surveys show 78 percent of adults between the ages of 50 and 64 would prefer to stay in their current residence as they age. The differences in cost between in home care and dedicated centers is dramatic. The fact of the matter is the longer a person can stay in their home, the more the savings and the closer the living environment is in line with that desired by all affected. The convergence in forces driving more adults to attempt to stay in their residence as they age presents a unique set of challenges and opportunities both social and technical. My presentation will discuss the challenges, opportunities and applications Pelesend currently has today and is currently moving forward on developing. Given the projected demographic shift and increasing capabilities of mobile technology, Pelesend believes there will be a huge increase in the need for specialty products, targeted medical devices and service offerings as result. We at Pelesend are well positioned to meet this demand with a strong platform already in place.
Speaker: Marc Bandt, CEO, Pelesend Inc
Date and Time: Tuesday, June 26, 2012, 8:30-10:30am
Location: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library)
Cost: Free

The New York Venture Summit, presented by youngStartup Ventures is the premier industry gathering where cutting-edge startups meet top venture capitalists, angel investors, Corporate VCs and investment bankers. Whether you are an investor seeking new deals, or an emerging company seeking capital and exposure, the The New York Venture Summit, is one event you won�t want to miss.
Speakers: More than 40 leading VCs will speak at the Summit.
Date and Time: June 27-28, 2012
Location: Digital Sandbox in New York City
Cost:
Discounted rate for BioCenter members! Mor info coming soon...

Gary Baker, Managing Director of the Quine IP Law Group, will discuss recent court cases, which effectively narrow the scope of acceptable subject matter for patent protection. In Mayo v. Prometheus (U.S. Supreme Court, No. 10�1150, argued December 7, 2011 - decided March 20, 2012), the relationship between serum thiopurine metabolite levels and the efficacy or toxicity of dosing was deemed an unpatentable law of nature. The Supreme Court held that simply appending conventional steps, specified at high level of generality, to laws of nature does not provide patentable subject matter.
Mr. Baker will discuss the history leading to Prometheus and possible practical effects with regard to analytical and treatment methods claims.
Immediately following the event, the BioCenter will host a Networking Dessert & Product Show, generously provided by Scientist Solutions Events. All attendees and BioCenter clients are invited to come out to enjoy food/refreshments/espresso bar/raffle and browse the vendor tables!
This workshop qualifies for MCLE credit. MCLE (Minimum Continuing Legal Education) refers to the approved continuing legal education required of California attorneys. Attorneys are required to complete a total of 25 hours of approved credit every three years.
Date and Time: June 28, 2012
Location: San Jose BioCenter, San Jose, CA
Cost:
Regular Price: $35
Partners' Network: $25
** BioCenter Members: Free

Stem cell derived therapeutics have enormous potential for their ability to restore and regenerate tissue function. CLT-008, a novel cellular therapeutic developed by Cellerant Therapeutics, is designed to provide hematopoietic support following high dose chemotherapy or exposure to radiation. It is a universal product derived from adult hematopoietic stem cells that have the ability to differentiate into functional neutrophils and platelets invivo. CLT-008 is currently being evaluated in two Phase 1 clinical trials. The talk will address issues and challenges related to the development and commercialization of cell-based therapies such as CLT-008.
Speaker: Ram Mandalam, Ph.D., President and CEO, Cellerant Therapeutics Inc.
Date and Time: Tuesday, July 10, 2012, 6:00 pm
Location: Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA
Cost: $6 - Students/In-transition - Members only
$11 - Early-bird Registration - Members only
$20 - Late Registration and Non-Members
$25 - Walk-ins

Modern medicine makes extensive use of high technology. On the other hand, medical decision-making is still rather opaque from the patient's point of view. How can we incorporate sound science and quantitative measures of diagnostic test effectiveness into a tool that physicians can use and explain to patients? We propose a visual approach using nomograms that not only facilitates the relevant calculations, but also enables better communication with the patient. Prostate specific antigen (PSA) screening, which has recently been heatedly discussed in the medical literature, will be used as an example in the determination of if and when such testing is appropriate. The outcome we seek is a more well-understood collaborative process that leads to less mental anguish, reduced pain and suffering, and lower overall testing and treatment cost. The talk is based on the recently published article: Marasco, J., Doerfler, R., and Roschier, L. 2011. Doc, What Are My Chances? The UMAP Journal 32 (4): 279-298. After 17 years with Rational Software, Joe Marasco retired in 2003 as a senior vice-president and business-unit manager. From 2005 to 2008, he was President and CEO of Ravenflow, a software startup addressing requirements definition using natural language processing. He holds a bachelor's degree in chemical engineering from The Cooper Union, a Ph.D. in physics from the University of Geneva, Switzerland, and an M.B.A. from the University of California, Irvine. He is the author of The Software Development Edge: Essays on Managing Successful Projects (Addison-Wesley, 2005), which has been translated into four languages.
Speaker: Joe Marasco
Date and Time: Tuesday, July 17, 2012, 8:30-10:30am
Location: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library)
Cost: Free

Externalization through partnering and collaboration is essential to the future success of the pharmaceutical and biotechnology industry. BioPartnering Future Europe� (BPFE) 2012 is a highly focused deal making conference in Europe, with Europe for the World. With support from the European Commission and a consortium of collaborators, BPFE has been designed to create an arena for partnering and collaborating that will ensure the future success of this industry. At the same time, BPFE will address all levels of business including capital raising, finance, policy issues, innovation in drug development, small and medium enterprises (SME�s) and the regulatory process.
Date and Time: October 7-9, 2012
Location: The Square, Brussels, Belgium
Cost:
Early Bird Rate (ends August 27): $1,950
General Rate (Aug 28 - Oct 5): $2,350
Onsite Rate (starts Oct 5) $2,600
Get a 10% Discount with Promotion Code "SJBio2012" ($1,710 to $1,900)

The BioExec Institute is an internationally renowned executive program delivered by leaders in the industry to director and vice president level managers who are searching for the keys to managing business trade-offs within a highly regulated and competitive industry.
Alongside BioExec Institute faculty and alumni, attendees will participate in a six-day (3 modules of 2 days each) interactive program, including three evening networking receptions. Participants will have unique opportunities to discuss and debate the strategies and tactics of business leadership within BioPharma and will complete the program with invaluable insight and powerful networks to deliver bottom-line value in this growing industry.
Day 0: Opening Night Welcome Reception
Day 1 - New Models of Innovation: Where does innovation come from and how do we get more of it? There are few more important questions to the biopharma industry and this year's BioExec Institute will feature some of the industries most respected thought leaders on the subject of innovation including Bernard Munos, Founder, InnoThink Center for Research in Biomedical Innovation and Mervyn J. Turner, Ph.D., Chief Strategy Officer, Merck & Co. Inc. & Sr. Vice President, Emerging Markets, Merck Research Laboratories.
Day 2 - Disruptive Innovation: A focus on innovative and/or niche models represented at specific companies which may or may not evolve into mainstream strategies. A high-level view of where current strategic investments are being made by �traditional� biopharmas.
Date: October 9-10, 2012
Location: Center for Executive Development at the Haas School of Business, UC Berkeley, 2220 Piedmont Avenue, S-480, Berkeley, CA 94720
Cost:
1 Module: $2,400
Full Program - Regular Registration: $6,900
Full Program - Early Enrollment Registration (by June 25, 2012): $5,500
Full Program - Program Scholarships: $3,000
Full Program - Corporate Special (3 registrations): $18,600

The upcoming 25th Annual Industry Growth Forum will feature presentations from 30 emerging clean energy companies, provocative panels led by thought leaders, one-on-one meetings, and organized networking opportunities. Since the Forum began, it has grown to be the perfect venue for growing companies to prepare, refine, and present their businesses to a wide range of investors. Each year, the best presenters are awarded cash prizes and commercialization services from NREL. This focus on clean energy innovation is having an impact on the industry�since 2003, the presenting prototype, pre-commercial, and expanding cleantech companies who have presented have collectively raised more than $4 billion in growth financing.

Deadline for startups to apply to present is July 13, 2012. For more information, and to apply, visit: http://www.industrygrowthforum.org.

The BioExec Institute is an internationally renowned executive program delivered by leaders in the industry to director and vice president level managers who are searching for the keys to managing business trade-offs within a highly regulated and competitive industry.
Alongside BioExec Institute faculty and alumni, attendees will participate in a six-day (3 modules of 2 days each) interactive program, including three evening networking receptions. Participants will have unique opportunities to discuss and debate the strategies and tactics of business leadership within BioPharma and will complete the program with invaluable insight and powerful networks to deliver bottom-line value in this growing industry.
Day 3: Strategic Product Positioning: Companies often start development on new or improved products because of great technological innovations in the lab. But, ultimately, it is the market - the customer - who decides whether your product is valuable or not. Planning for commercial success starts at the research stage and parallels the entire R&D; process. During this session, industry leaders will explore product commercialization, second generation products and potential exit strategies, all in an effort to determine the best way to optimize the value of innovation over time. The content in this session will range from high-level strategic trade-offs to detailed calculations of value (both quantitative and qualitative) and from debating options to understanding the path for optimizing your company's assets.
Mid-Point Networking Reception
Day 4: Successfully Operating in a Global Regulatory Environment: Bringing products to market requires overcoming significant regulatory challenges for the goal of delivering on the safety and efficacy of the product. This session deals with the many gray areas of moving the product through the regulatory process, and understanding the various stakeholders' goals and political trade-offs in making the decision of whether or not to approve the product. Understanding the key questions that are core to each of the stakeholders unveils the secrets to getting a drug approved and plays an important role to a company's commercialization strategy. Topics covered in this session include, but not limited to, the importance of designing appropriate clinical trials to support a strong product label, DOJ and FDA specific promotional interests, substantial evidence, fair balance, understanding the basics of clinical support, medical affairs organizations and regulatory considerations, pre-approval activities, public relations programs, medical conventions, the EMEA and Japan regulatory requirements and how to meet those.
Date: November 7-8, 2012
Location: Center for Executive Development at the Haas School of Business, UC Berkeley, 2220 Piedmont Avenue, S-480, Berkeley, CA 94720
Cost:
1 Module: $2,400
Full Program - Regular Registration: $6,900
Full Program - Early Enrollment Registration (by June 25, 2012): $5,500
Full Program - Program Scholarships: $3,000
Full Program - Corporate Special (3 registrations): $18,600

The BioExec Institute is an internationally renowned executive program delivered by leaders in the industry to director and vice president level managers who are searching for the keys to managing business trade-offs within a highly regulated and competitive industry.
Alongside BioExec Institute faculty and alumni, attendees will participate in a six-day (3 modules of 2 days each) interactive program, including three evening networking receptions. Participants will have unique opportunities to discuss and debate the strategies and tactics of business leadership within BioPharma and will complete the program with invaluable insight and powerful networks to deliver bottom-line value in this growing industry.
Day 5 - Deal-Maker for a Day: Licensing and partnering are an integral part of the Biopharmaceutical industry. The formerly distinct pharmaceutical and biotechnology industries are merging into one interdependent Biopharmaceutical Industry. Partnered products are the future of innovation leading to a significant increase in attempts to acquire and/or license innovation from others. Big pharmaceutical companies will control fewer and fewer of their new products from discovery through line extension or OTC. This Day explores the underlying economics of deals; the different strategies for measuring risk; and how decisions are made amidst uncertainty.
Closing Networking Reception
Day 6 - CEO for a Day: Being a successful CEO is a mix of timing, teams and some say luck. On Day 6 of the BioExec Institute you will not only have the opportunity to dialogue with some of the industries most respected CEOs who will provide detailed and candid accounts of what really happened, but you will become a CEO for the day. You will be asked to make strategic decisions based on little to no information; you will be faced with contentious Board Members and disgruntled employees. What will your financing or exit strategy be and who will you be crowned the Winner of CEO for a Day by BioExec Faculty?
Date: December 6-7, 2012
Location: Center for Executive Development at the Haas School of Business, UC Berkeley, 2220 Piedmont Avenue, S-480, Berkeley, CA 94720
Cost:
1 Module: $2,400
Full Program - Regular Registration: $6,900
Full Program - Early Enrollment Registration (by June 25, 2012): $5,500
Full Program - Program Scholarships: $3,000
Full Program - Corporate Special (3 registrations): $18,600